HighTide

HighTide Therapeutics, Inc. is a globally integrated biotechnology company focused on addressing significant unmet clinical needs in the fields of metabolic and digestive diseases. Led by an experienced international executive team and a world-class scientific advisory board, the company emphasizes original innovation, aiming to improve patients' overall clinical benefits and holistic health through the development of First-in-Class, multi-functional, and multi-indication novel drugs. Based on proprietary intellectual property, the company has established a robust product pipeline and is advancing multiple mid-to-late stage clinical trials worldwide for indications such as nonalcoholic steatohepatitis (NASH), type 2 diabetes mellitus (T2DM), severe hypertriglyceridemia (SHTG), primary sclerosing cholangitis (PSC), and primary biliary cholangitis (PBC). As a first-in-class multi-target new molecular entity, HTD1801 has been granted two "Fast Track Designations" and one "Orphan Drug Designation" by the U.S. FDA, and has received support from China's "13th Five-Year Plan" Major Science and Technology Project for "Significant New Drug Development."